Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
Stopped The trial prematurely terminated due to the inability to recruit the planned number of participants. The decision to terminate the trial was not based on any safety and/or efficacy concerns.
Conditions
Sponsor
Pfizer